Full access

Symposia content will be available to view on the Kidney Week 2021 Platform through Friday, January 7, 2022

Continuing Education Credit

These activities are eligible for continuing education credit. For more information, please visit www.ASN-online.org/KidneyWeek.

Thursday, November 4

  • More Options and More to Come: Update on the Management of Lupus Nephritis

  • Support is provided by an educational grant from GlaxoSmithKline.

  • New Insights in Iron Deficiency Anemia Among Patients with Non-Dialysis CKD

  • Support is provided by an educational grant from Akebia Therapeutics, Inc.

  • Partners for Life: Optimizing Collaboration of Community and Transplant Nephrologists

  • Support is provided by an educational grant from Natera.

  • SGLT2 Inhibitors: Should We Put Them in the Water of Patients with CKD?

  • Support is provided by an educational grant from AstraZeneca Pharmaceuticals.

  • Update on Genetic Architecture and Therapy of Polycystic Kidney Diseases

  • Support is provided by an educational grant from Otsuka America Pharmaceutical, Inc.

Friday, November 5

  • Basics to Bedside: State-of-the-Art Rationale and Approach to Hyperkalemia in Kidney Diseases

  • Support is provided by an educational grant from Vifor Pharma, Inc.

  • Current Therapies and Treatment Responses in Primary Focal Segmental Glomerulosclerosis and IgA Nephropathy

  • Support is provided by an educational grant from Travere Therapeutics, Inc.

  • Hepatorenal Syndrome Type 1: Advances in Management

  • Support is provided by an educational grant from Mallinckrodt Pharmaceuticals.

  • Mineralocorticoid Receptors: From Bedside to Bench and Back

  • Support is provided by an educational grant from Bayer HealthCare Pharmaceuticals Inc.

  • Uremic Toxin Removal with Dialysis: Effects of Middle Molecule Clearance on Clinical Outcomes

  • Support is provided by an educational grant from Baxter Healthcare Corporation.

Saturday November 6

  • Emerging Paradigms in Primary Hyperoxaluria Type 1

  • Support is provided by an educational grant from Alnylam Pharmaceuticals, Inc.

  • HIF-PHIs Offer Hope for Anemia in CKD

  • Support is provided by an educational grant from Akebia Therapeutics, Inc. and Otsuka America Pharmaceutical, Inc.

  • Knowing Your Options: Understanding Therapies for Hyperkalemia Management to Aid Decision-Making with Patients Treated with Hemodialysis

  • Support is provided by an educational grant from AstraZeneca Pharmaceuticals.

  • Update on the Epidemiology, Pathogenesis, and Treatment of CKD-Associated Pruritus

  • Support is provided by an educational grant from Cara Therapeutics, Inc. and Vifor Pharma, Inc.

Save